The recommendations listed in this guideline are, whenever possible, evidence based. An
initial extensive evidence review, which included literature derived from research involving …

The recommendations listed in this guideline are, whenever possible, evidence based An
initial extensive evidence review, which included literature derived from research involving …

BIOTRONIK's First in Man study of the Passeo-18 LUX drug releasing PTA Balloon Catheter
vs. the uncoated Passeo-18 PTA balloon catheter in subjects requiring revascularisation of …

Peripheral arterial disease (PAD) continues to grow in global prevalence and consumes an
increasing amount of resources in the United States health care system. Overall rates of …

The Trans-Atlantic Inter-Society Consensus Document on Management of Peripheral
Arterial Disease (TASC) was published in January 2000 1-3 as a result of cooperation …

Peripheral arterial disease (PAD) affects 15% of the Australian population and is a powerful
and serious predictor of cardiovascular mortality yet continues to be under-recognised and …

Peripheral artery disease (PAD) is a manifestation of systemic atherosclerosis. Modifiable
risk factors including cigarette smoking, dyslipidemia, diabetes, poor diet quality, obesity …

Peripheral arterial disease (PAD) is a condition characterized by atherosclerotic occlusive
disease of the lower extremities. On May 7-8, 2003, a Consensus Development Conference …

Peripheral arterial disease, which is caused by atherosclerotic occlusion of the arteries to
the legs, is an important manifestation of systemic atherosclerosis. The age-adjusted …

These guidelines address the diagnosis and management of atherosclerotic, aneurysmal,
and thromboembolic peripheral arterial diseases (PADs). The clinical manifestations of PAD …